EUVIMEDEUVIMED entdecken
Crossref

Cardiovascular morbidity following conventional therapy versus allogeneic hematopoietic stem cell transplantation after childhood, adolescent, and young adult leukemia in Finland

Andreina E Kero iD, Mervi Taskinen, Liisa Volin, Eliisa Löyttyniemi, Maija Itälä-Remes, Päivi M Lähteenmäki iD

International Journal of Cancer · 2023-06 · 152 (11) · 2292-2302

DOI: 10.1002/ijc.34469 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 21.02.2023. Verfasst von Andreina E Kero und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Turku University Hospital, and Turku University, Turku, Finland. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Cardiovascular Diseases, Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Lastentautien Tutkimussäätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic stem cell transplantation (aHSCT) represents a therapeutic choice for high‐risk and relapsed leukemia at a young age. In this retrospective population‐based study, we evaluated cardiovascular complications after aHSCT (N = 272) vs conventional therapy (N = 1098) among patients diagnosed with acute lymphoblastic or acute myeloid leukemia below 35 years between 1985 and 2004. Additionally, siblings from a prior comparison group served as population controls (N = 39 217). Childhood leukemia and aHSCT was associated with a 16‐fold HR for developing arterial hypertension (HR 16.8, 95%CI 1.5‐185.5) compared with conventional therapy. A 2‐fold HR for any cardiovascular complication was observed after AYA leukemia and aHSCT vs conventional treatment (HR 2.7, 95% CI 1.4‐5.1). After AYA leukemia and aHSCT, the HR of cardiac arrhythmia was significantly elevated vs conventional therapy (HR 14.4, 95% CI 1.5‐125.2). Moreover, after aHSCT in childhood, elevated hazard ratios (HRs) were found for cardiomyopathy/ cardiac insufficiency (HR 105.0, 95% CI 10.0‐1100.0), cardiac arrhythmia, and arterial hypertension (HR 20.1, 95%CI 2.5‐159.7 and HR 20.0, 95%CI 4.1‐97.4) compared with healthy controls. After adolescent and young adult (AYA) leukemia and aHSCT, markedly increased HRs were observed for cardiac arrhythmia (HR 29.2, 95%CI 6.6‐129.2), brain vascular thrombosis/ atherosclerosis and cardiomyopathy/cardiac insufficiency (HR 23.4, 95%CI 7.1‐77.4 and HR 19.2, 95%CI 1.5‐245.2) compared with healthy controls. As the cumulative incidence for cardiovascular complications rose during the follow‐up of childhood and AYA leukemia patients, long‐term cardiovascular surveillance is warranted to optimize the quality of life after childhood and AYA leukemia following both conventional treatment and aHSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationCardiovascular DiseasesHypertensionHumansAdolescentYoung AdultRetrospective StudiesFinlandQuality of Life

Stichwörter der Autor:innen

acute leukemiaallogeneic hematopoietic stem cell transplantationcancercardiovascular morbidityconventional cancer treatmentepidemiologyregistry study

Autor:innen und Institutionen

  • Department of Pediatrics and Adolescent Medicine, Turku University Hospital, and Turku University, Turku, Finland.
  • New Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
  • Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
  • Department of Biostatistics, University of Turku, Turku, Finland.
  • Department of Internal Medicine, Turku University Hospital, Turku, Finland.

ORCID-Profile: Andreina E Kero, Päivi M Lähteenmäki

Förderung

  • Lastentautien Tutkimussäätiö

Zitieren

APA

Kero, A. E., Taskinen, M., Volin, L., Löyttyniemi, E., Itälä-Remes, M., & Lähteenmäki, P. M. (2023). Cardiovascular morbidity following conventional therapy versus allogeneic hematopoietic stem cell transplantation after childhood, adolescent, and young adult leukemia in Finland. International Journal of Cancer, 152(11), 2292-2302. https://doi.org/10.1002/ijc.34469

Vancouver

Kero AE, Taskinen M, Volin L, Löyttyniemi E, Itälä-Remes M, Lähteenmäki PM. Cardiovascular morbidity following conventional therapy versus allogeneic hematopoietic stem cell transplantation after childhood, adolescent, and young adult leukemia in Finland. International Journal of Cancer. 2023;152(11):2292-2302. doi:10.1002/ijc.34469

BibTeX
@article{Kero2023,
  author = {Kero, Andreina E and Taskinen, Mervi and Volin, Liisa and Löyttyniemi, Eliisa and Itälä-Remes, Maija and Lähteenmäki, Päivi M},
  title = {Cardiovascular morbidity following conventional therapy versus allogeneic hematopoietic stem cell transplantation after childhood, adolescent, and young adult leukemia in Finland},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {152},
  number = {11},
  pages = {2292--2302},
  doi = {10.1002/ijc.34469}
}
Kostenlos starten →